CDK4 and neoplasm: Additionally, although the combined inhibition of BRAF, MEK, and CDK4/6 has shown promising anti-tumor effects, flow cytometry analysis has indicated that the massive infiltration of tumor-infiltrating myeloid cells may have an adverse impact on anti-tumor immunity in melanoma [105].